Odyssey Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-148.65	-129.32	-125.94	-124.67
Depreciation & Amortization	4.91	5.19	4.91	2.76
Stock-Based Compensation	14.32	8.69	6.26	5.52
Other Adjustments	4.67	1.28	1.15	17.09
Changes in Accounts Payable	2.06	-1.7	2.24	3.27
Changes in Accrued Expenses	-4.15	3.13	-1.08	6.88
Changes in Other Operating Activities	-2.64	-4.74	-0.26	-10.69
Operating Cash Flow	-129.47	-117.47	-112.73	-99.84
Capital Expenditures	-1.23	-0.76	-5.06	-13.03
Sale of Property, Plant & Equipment	0.36	-	0.02	-
Purchases of Investments	-208.97	-52.61	-238.11	-
Proceeds from Sale of Investments	105.9	150.16	78.12	-
Investing Cash Flow	-103.94	96.78	-165.02	-13.03
Long-Term Debt Issued	-	-	-4.76	4.88
Net Long-Term Debt Issued (Repaid)	-	-	-4.76	4.88
Issuance of Common Stock	3.19	0.51	0.26	0.08
Net Common Stock Issued (Repurchased)	3.19	0.51	0.26	0.08
Issuance of Preferred Stock	212.46	27.48	96.57	177.77
Net Preferred Stock Issued (Repurchased)	212.46	27.48	96.57	177.77
Other Financing Activities	-	-1.01	-	-
Financing Cash Flow	215.65	26.98	92.08	182.72
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.32	0.05	0.01	-0.02
Net Cash Flow	-17.45	6.34	-185.67	69.83

SEC Filings: 10-K · 10-Q